3.
多因素分析NSCLC特异性生存率的预后因素（n=47）
Cox regression analysis of the disease-specific survival of NSCLC patients (n=47)
| Characteristic | Regression coefficient β | Standard error | Wald | P | Exp(B) | 95%CI |
| Progression free survival | ||||||
| Gender | 0.339 | 0.478 | 0.503 | 0.478 | 1.403 | 0.550-3.577 |
| Age | 0.418 | 0.433 | 0.929 | 0.335 | 1.519 | 0.649-3.551 |
| Pathological type | 0.186 | 0.380 | 0.240 | 0.624 | 1.205 | 0.572-2.538 |
| Differentiation | -0.131 | 0.316 | 0.173 | 0.677 | 0.877 | 0.472-1.628 |
| Metastasis | -0.023 | 0.427 | 0.003 | 0.956 | 0.977 | 0.423-2.254 |
| Chemotherapeutic regimen | 0.237 | 0.221 | 1.151 | 0.283 | 1.268 | 0.822-1.956 |
| Keap1 | -1.079 | 0.398 | 7.358 | 0.007 | 0.340 | 0.156-0.741 |
| Overall survival | ||||||
| Gender | 0.288 | 0.657 | 0.193 | 0.661 | 1.334 | 0.368-4.831 |
| Age | -0.421 | 0.683 | 0.380 | 0.538 | 0.657 | 0.172-2.504 |
| Pathological type | -2.212 | 0.992 | 4.976 | 0.026 | 0.109 | 0.016-0.765 |
| Differentiation | 0.863 | 0.587 | 2.164 | 0.141 | 2.370 | 0.751-7.486 |
| Number of chemo therapeutic regimen | -0.904 | 0.454 | 3.966 | 0.046 | 0.405 | 0.166-0.986 |
| EGFR-TKI treatment | -2.375 | 0.880 | 7.290 | 0.007 | 0.093 | 0.017-0.522 |
| Keap1 | -0.276 | 0.716 | 0.149 | 0.700 | 0.759 | 0.186-3.088 |
| EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor. | ||||||